Related coverage linked through entity extraction aliases.
Mar 14, 2026
AbbVie shares declined 2% on March 13, 2026, amid reduced trading volume, while BMO Capital maintained its Outperform rating following Phase 1 obesity drug trial data for ABBV-295.
Mar 14, 2026
AbbVie reported Q4 earnings that beat consensus estimates with $16.62 billion in revenue, while facing competitive setbacks in psoriatic arthritis and Medicare pricing challenges for Botox.
Mar 03, 2026
The FDA informed uniQure that Phase 1/2 study data for AMT-130 in Huntington's disease is insufficient to support a biologics license application, recommending a prospective, randomized, double-blind, sham surgery-controlled study instead.
Feb 28, 2026
Johnson & Johnson stock hit an all-time high of $246.54, up 54.05% over the past year. The company announced a $1 billion investment in a Pennsylvania cell therapy facility and received upgraded price targets from major financial firms.
Feb 17, 2026
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Feb 14, 2026
Johnson & Johnson shares have climbed 53% over the past year and 15% year-to-date, with RBC Capital and Bank of America raising price targets on the stock amid strong financial performance and 6% revenue growth in 2025.
Feb 13, 2026
Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study showing 100% acute procedural success with zero adverse events in treating symptomatic paroxysmal atrial fibrillation across 30 patients.
